Repurposing cardiac glycosides for anticancer treatment: a review of clinical studies.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Ltd. Country of Publication: England NLM ID: 9604391 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-5832 (Electronic) Linking ISSN: 13596446 NLM ISO Abbreviation: Drug Discov Today Subsets: MEDLINE
    • Publication Information:
      Original Publication: Kidlington, Oxford : Irvington, NJ : Elsevier Science Ltd. ; Distributed by Virgin Mailing and Distribution, c1996-
    • Subject Terms:
      Cardiac Glycosides*/pharmacology ; Cardiac Glycosides*/therapeutic use ; Drug Repositioning*/methods ; Antineoplastic Agents*/therapeutic use ; Antineoplastic Agents*/pharmacology ; Neoplasms*/drug therapy; Humans ; Animals ; Quality of Life
    • Abstract:
      Cardiac glycosides (CGs), which are traditionally used for heart disease, show promise for cancer therapy. However, there is a lack of a comprehensive review of clinical studies in this area, and so far, CGs have not been widely integrated into clinical cancer treatment. This review covers clinical studies from the past five years, highlighting the potential of CGs to reduce cancer risk, enhance chemotherapy effectiveness, mitigate chemotherapy-induced side effects and improve quality of life. Future clinical trials should personalize the dosage of CGs, integrate molecular testing and investigate immunogenic cell death induction and the potential of CGs for treating bone cancer and metastasis. Optimizing the repurposing of CGs for anticancer treatment requires consideration of specific CGs, cancer types and concurrent medications.
      (Copyright © 2024 Elsevier Ltd. All rights reserved.)
    • Contributed Indexing:
      Keywords: Antitumor; Cardiac glycoside; Cinobufacini; Cinobufagin; Digitalis; Digoxin
    • Accession Number:
      0 (Cardiac Glycosides)
      0 (Antineoplastic Agents)
    • Publication Date:
      Date Created: 20240804 Date Completed: 20240920 Latest Revision: 20240920
    • Publication Date:
      20240921
    • Accession Number:
      10.1016/j.drudis.2024.104129
    • Accession Number:
      39098384